d-penicillamine

DEVICE2 trials

Sponsors

FDA Office of Orphan Products Development, Orphalan

Conditions

Lead PoisoningVitamin D DeficiencyWilson's Disease

Phase 2

Penicillamine Chelation for Children With Lead Poisoning

WithdrawnNCT00552630

FDA Office of Orphan Products DevelopmentLead Poisoning, Vitamin D Deficiency

Start: 2007-09-30Updated: 2015-03-26

Phase 3

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

Not yet recruitingNCT07465718

OrphalanWilson's Disease

Start: 2026-08-01End: 2028-02-01Target: 38Updated: 2026-08-05